Understanding Type 1 Diabetes as a Progressive Disease—and a New Approach to Slowing It

Type 1 diabetes is a chronic autoimmune disease that develops gradually, often over years, before a person experiences symptoms. This progressive nature means the disease has multiple stages—including a long period when the immune system is actively attacking insulin-producing cells but the person feels fine.

During these early stages, autoimmunity is happening in the background while pancreatic beta cells—the cells that make insulin—are slowly lost. This creates a critical window: a time when intervention might be possible before diabetes fully develops and symptoms appear.

Once Type 1 diabetes is diagnosed, the damage is already substantial. The disease disproportionately affects children and adolescents, and it carries real risks: diabetic ketoacidosis, long-term complications affecting the eyes, kidneys, and cardiovascular system, and reduced life expectancy.

Even with modern tools like insulin pumps and continuous glucose monitors, most people with Type 1 diabetes struggle to achieve optimal blood sugar control. This translates into ongoing medical risk and, for many, substantial psychological stress.

The burden extends beyond day-to-day management. People with Type 1 diabetes face the cumulative threat of long-term complications—damage to small blood vessels affecting the eyes and kidneys, as well as damage to larger blood vessels affecting the heart and brain. The disease also increases the risk of diabetic ketoacidosis, a potentially life-threatening condition.

Because Type 1 diabetes develops in stages, scientists and doctors are exploring a different approach: intervening early, before stage 3 diabetes develops, to try to slow or delay disease progression.

Teplizumab (Tzield) is an anti-CD3 monoclonal antibody—a type of immunotherapy—that has been approved by the FDA as the first therapy specifically designed to delay the progression from stage 2 to stage 3 Type 1 diabetes. It is approved for use in people ages 8 years and older.

This represents a paradigm shift in how Type 1 diabetes is managed: rather than focusing only on insulin delivery and blood sugar control after diagnosis, doctors now have a tool that may delay disease onset itself and potentially reduce long-term complications.

Teplizumab and similar disease-modifying immunotherapies work by intervening in the autoimmune process—targeting the immune system's attack on beta cells rather than just replacing the insulin those cells produce.

The emerging evidence shows that this approach has potential to change the trajectory of Type 1 diabetes in people at high risk. However, these are early days. Disease-modifying therapies represent a new frontier, and ongoing research continues to explore how best to use these tools and which patients may benefit most.

Source: JAAPA : official journal of the American Academy of Physician Assistants. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.